All articles tagged with #metsera
Pfizer beat Q1 2026 estimates with adjusted EPS of 75 cents and revenue of $14.45 billion, reaffirming its 2026 guidance as growth from newly launched and acquired drugs offsets declines in Covid vaccine and Paxlovid sales; the company is pursuing long-term pipeline investments, notably a $10 billion Metsera acquisition, with 2026 targets of about $2.80–$3.00 in adjusted EPS and $59.5–$62.5 billion in revenue.
Pfizer beat Q4 estimates with adjusted EPS of 66 cents on $17.56 billion in revenue, despite weaker demand for its Covid vaccine and Paxlovid; it reaffirmed a modest 2026 outlook, plans about $7.7 billion in cost cuts by 2027, and is betting on long-term growth from the Metsera acquisition, including obesity therapy data, while facing ongoing price pressure in Medicaid and competitive pressures on older drugs.
Pfizer's $10 billion acquisition of Metsera, a company developing experimental weight loss drugs, highlights significant activity in biotech mergers and investments, with venture funds like Population Health Partners and ARCH Venture Partners poised to profit greatly. The deal underscores both opportunities and cautionary lessons in biotech M&A and investment strategies.
Pfizer has acquired Metsera for up to $10 billion in a high-stakes deal to enter the obesity treatment market, aiming to recover from past struggles in this sector and boost its declining COVID-19 vaccine sales. The success of the investment remains uncertain, with Pfizer CEO Albert Bourla acknowledging the risk of overpaying if the venture fails or gaining a significant advantage if it succeeds.
Pfizer will acquire Metsera for up to $10 billion after a bidding war with Novo Nordisk, with the deal expected to close soon. Metsera's stock fell over 15% following the announcement, despite its initial surge after going public in January. The acquisition aims to strengthen Pfizer's position in obesity treatment, leveraging Metsera's midstage GLP-1 drug and potential monthly therapies.
Pfizer has agreed to acquire weight-loss drug startup Metsera in a deal potentially worth over $10 billion, outbidding Novo Nordisk amid a competitive market for obesity treatments. The deal includes cash and performance-based payouts, giving Pfizer access to new obesity therapies and strengthening its position in a rapidly growing market. The transaction is expected to close after shareholder approval, with Pfizer aiming to leverage its global scale to expand obesity drug development.
Pfizer has won the bid to acquire Metsera, a development-stage obesity drug company, surpassing Novo Nordisk in a competitive deal valued at up to $86.25 per share, as both companies vie to expand their presence in the obesity and diabetes treatment markets.
Novo Nordisk's CEO Mike Doustdar withdrew from a $10 billion bid for Metsera after Pfizer matched its offer, highlighting intense competition in the obesity drug market. Despite setbacks, Novo plans to pursue other acquisitions and focus on its pipeline, including new treatments and potential breakthroughs like a pill form of semaglutide. The company is shifting towards a more aggressive, market-driven approach to regain its leadership in the booming weight-loss industry.
Novo Nordisk has abandoned its bid for Metsera after Pfizer secured a $10 billion deal to acquire the U.S. weight-loss drug developer, ending a competitive bidding war.
Pfizer agreed to acquire Metsera for $10 billion after a bidding war with Novo Nordisk, with Pfizer securing US regulatory approval and offering a higher bid, aiming to strengthen its position in the growing obesity drug market.
Pfizer has accepted a $10 billion bid to acquire Metsera, potentially ending a bidding war with Novo Nordisk over obesity drug assets, with the deal expected to close after Metsera's November 13 shareholder meeting.
Pfizer has won a $10 billion bidding war to acquire the weight-loss start-up Metsera, marking a significant move in the pharmaceutical industry.
Pfizer has agreed to acquire Metsera for $10 billion, ending a bidding war with Novo Nordisk over a promising obesity drug portfolio, with Pfizer offering a premium price and contingent payments, while Metsera's board recommends shareholders accept the deal amid ongoing market competition.
Novo Nordisk has increased its bid in the ongoing competition to acquire the obesity start-up Metsera, highlighting its strategic interest in expanding its footprint in the biotech and obesity treatment sectors.
Novo Nordisk has increased its bid for Metsera in an effort to outbid Pfizer's latest offer, as part of a competitive acquisition process.